Bli medlem
Bli medlem

Du är här

2017-10-02

Nuevolution: Redeye: A good BET in Nuevolution

Nuevolution has a transforming year behind them and more updates are
expected by the end of the year. We see the BET-inhibitor program as
the most interesting from a partnering perspective and the prospects
for a licensing deal are good. Further, an additional drug discovery
collaboration deal has a good possibility of being realized. In this
new Research Update Mathias Spinnars is summing up the fiscal year
2016/17, what lies ahead and the valuation of the company. Continue
reading at: https://goo.gl/j6MkGi

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se

-----------------------------------------------------------
http://news.cision.com/se/nuevolution/r/redeye--a-good-bet-in-nuevolutio...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.